AI-generated summary
The authors reappraise five studies often cited as evidence that photobiomodulation may stimulate tumour growth or cause phototoxicity, using each study's own reported dosimetry. They report that four of the five used exposures outside the therapeutic window, with surface temperatures up to 71 °C and irradiances about 25 times clinical levels. The fifth, a xenograft study at a therapeutic dose, used an immunodeficient host, which the authors say cannot express the immune response at issue.
- Studies included
- 5
- Who or what was studied
- Five experimental studies cited as evidence of photobiomodulation-related tumour growth or phototoxicity, plus one internal control study from the same group.
- Limits stated in the abstract
- The authors state that none of the studies characterised the spatial power distribution of the beam, and the xenograft study used an immunodeficient host.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Five studies are frequently cited as experimental evidence that photobiomodulation (PBM) may stimulate tumour growth or produce phototoxicity, contributing to a documented barrier to clinical adoption in oncology. We reappraise these studies against their own reported dosimetry. None characterised the spatial power distribution of its beam. Each was assessed for arithmetic consistency, beam profile, device category, and biological-model appropriateness, and re-examined against the Arrhenius framework for thermal damage. In four of the five, the exposures delivered lay outside the therapeutic photobiological window on the authors' own stated parameters: surface temperatures of 55 °C and, in places, 71 °C, with injury the original authors describe as coagulation and necrosis extending to paralysis and death; irradiances approximately 25 times those used clinically; and, in one case, parameters the authors themselves describe as high. The fifth, a xenograft study, used a dose within the therapeutic range, but its immunodeficient host cannot express the immune-mediated response at issue. A sixth study, from the same group and using the same device as one of the five but operated at a therapeutic irradiance, is included as an internal control and reported therapeutic benefit. Injury in these regimes is best understood as oxygen-dependent, with temperature acting as a sensitising variable and as a marker of the regime rather than as the proximate cause, a reading supported by the original authors' own helium-substitution, cooling and heated-probe controls. We outline a two-tier mechanistic framework, in which correctly dosed PBM may engage systemic anti-tumour immunity, as a hypothesis for prospective testing rather than as a finding of this analysis. None of these studies provides dosimetrically secure evidence of a hazard from therapeutic-range PBM; equally, the absence of such evidence is not a demonstration of safety. Beam-profile reporting should become standard in PBM oncology research.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Irradiance, Dosimetry, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.